[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

…, C Dooms, W Weder, D De Ruysscher, C Le Pechoux… - Annals of …, 2015 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer

L Schrevens, N Lorent, C Dooms… - The oncologist, 2004 - academic.oup.com
C-thymidine was the first radiotracer for noninvasive imaging of tumor proliferation. The
short half-life of 11 C and the rapid metabolism of 11 C-thymidine in vivo made the radiotracer …

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

M Dietel, L Bubendorf, AMC Dingemans, C Dooms… - Thorax, 2016 - thorax.bmj.com
Background There is currently no Europe-wide consensus on the appropriate preanalytical
measures and workflow to optimise procedures for tissue-based molecular testing of non-…

[HTML][HTML] Perioperative pembrolizumab for early-stage non–small-cell lung cancer

…, SH Lee, S Gao, KN Chen, C Dooms… - … England Journal of …, 2023 - Mass Medical Soc
Background Among patients with resectable early-stage non–small-cell lung cancer (NSCLC),
a perioperative approach that includes both neoadjuvant and adjuvant immune …

Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial

JT Annema, JP Van Meerbeeck, RC Rintoul, C Dooms… - Jama, 2010 - jamanetwork.com
Context Mediastinal nodal staging is recommended for patients with resectable non–small
cell lung cancer (NSCLC). Surgical staging has limitations, which results in the performance …

[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

…, L Crino, C Dooms, JY Douillard, C Faivre-Finn… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer

P De Leyn, C Dooms, J Kuzdzal… - European journal of …, 2014 - academic.oup.com
Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with
potentially resectable non-small-cell lung cancer (NSCLC) is of paramount importance. In 2007, …

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

…, E Felip, BJ Solomon, SS Ramalingam, C Dooms… - The Lancet, 2023 - thelancet.com
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C
. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …

[HTML][HTML] Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages

…, R Schepers, E Heylen, D Dauwe, C Dooms… - Cell research, 2021 - nature.com
How the innate and adaptive host immune system miscommunicate to worsen COVID-19
immunopathology has not been fully elucidated. Here, we perform single-cell deep-immune …

[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

…, C Dooms, W Weder, D De Ruysscher, C Le Pechoux… - Annals of …, 2014 - Elsevier
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages
(adverse events, … Dooms have declared no potential conflicts of interest. Dr. Crinò and Prof. …